Skip to main content
. 2022 Aug 2;12:816198. doi: 10.3389/fonc.2022.816198

Figure 4.

Figure 4

Correlation of timing between camrelizumab administration and TACE with survival. Correlation of timing between camrelizumab administration and TACE with PFS (A) and OS (B) in HCC patients receiving camrelizumab plus TACE. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PFS, progression-free survival; OS, overall survival.